Save up to 30% on Elsevier print and eBooks with free shipping. No promo code needed.
Save up to 30% on print and eBooks.
Advances in Clinical Chemistry
1st Edition, Volume 71 - September 24, 2015
Editor: Gregory S. Makowski
Language: English
Hardback ISBN:9780128022566
9 7 8 - 0 - 1 2 - 8 0 2 2 5 6 - 6
eBook ISBN:9780128025222
9 7 8 - 0 - 1 2 - 8 0 2 5 2 2 - 2
Advances in Clinical Chemistry, Volume 71, is the latest installment in this internationally acclaimed series. This latest volume contains chapters authored by world-ren…Read more
Purchase options
LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
is the latest installment in this internationally acclaimed series. This latest volume contains chapters authored by world-renowned clinical laboratory scientists, physicians, and research scientists. The serial discusses the latest and most up-to-date technologies related to the field of clinical chemistry and is the benchmark for novel analytical approaches in the clinical laboratory.
Expertise of international contributors
Latest cutting-edge technologies
Preface
Chapter One: Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
Abstract
1 Use of Biomarkers in the Identification of Women at Increased Risk of Developing Breast Cancer (Risk Assessment)
2 Use of Biomarkers in Determining Prognosis
3 Use of Biomarkers in Guiding Treatment
4 Use of Biomarkers in the Postoperative Follow-Up of Asymptomatic Patients Following Curative Surgery
5 Use of Biomarkers in Monitoring Therapy in Patients with Metastasis
6 Emerging Biomarkers for Breast Cancer
7 Conclusion
Acknowledgments
Chapter Two: Polycystic Ovary Syndrome-Epigenetic Mechanisms and Aberrant MicroRNA
Abstract
1 Introduction
2 The Epigenetic Landscape
3 miRNA
4 Conclusions
Acknowledgments
Chapter Three: EN2 in Prostate Cancer
Abstract
1 Introduction
2 Risk Factors and Conventional Biomarkers of Prostate Cancer
3 Biomarkers with Clinical Application in Urine
4 Antitumor Antibodies as Biomarkers
5 The Homeobox Gene Superfamily
6 The Biology of En
7 En in Cancer
8 En as a Potential Biomarker in Cancer
9 EN2 in Prostate Cancer
10 EN2 as a Diagnostic Marker and Marker of Significant Disease
11 EN2 in Men at High Risk of Prostate Cancer
12 Future Perspectives
13 Conclusion
Chapter Four: Cytochrome P450 in Cancer Susceptibility and Treatment
Abstract
1 Introduction
2 Classification, Nomenclature, and Structure of Cytochromes P450
3 Drug Metabolism
4 Genetic Variations in CYP450 Isoforms
5 CYP450 in Cancer Susceptibility
6 CYP450 in Anticancer Therapy
7 Conclusion
Acknowledgments
Chapter Five: The Importance of Accurately Assessing Renal Function in the Neonate and Infant
Abstract
1 Introduction
2 The Normal Development of Renal Function Before Birth
3 Adaptation of Hemodynamics and Renal Function After Birth
4 Can Nephrogenesis Continue After Preterm Birth?
5 Measuring Renal Function
6 Neonatal Kidney Size and Renal Function in Preterm Infants
7 Should We Move to CysC-Derived eGFR When Dosing Aminoglycosides and Other Renally Excreted in Neonates?
Acknowledgments
Chapter Six: Systematic Assessment of the Hemolysis Index: Pros and Cons
Abstract
1 Introduction
2 The Hemolysis Index
3 Pros and Cons
4 Conclusions
Chapter Seven: Peroxisome Proliferator-Activated Receptor α in Lipid Metabolism and Atherosclerosis
Abstract
1 Introduction
2 PPARα Expression
3 PPARα Structure and Activation
4 PPARα and Lipid Metabolism
5 PPARα and Lipoprotein Metabolism
6 The Roles of PPARα in Atherosclerosis
7 Therapeutic Potential of PPARα Agonists in Atherosclerosis and Dyslipidemia
8 Conclusions and Perspectives
Acknowledgments
Index
No. of pages: 220
Language: English
Edition: 1
Volume: 71
Published: September 24, 2015
Imprint: Academic Press
Hardback ISBN: 9780128022566
eBook ISBN: 9780128025222
GM
Gregory S. Makowski
Dr Gregory S Makowski is a board certified clinical chemist and fellow of the National Academy of Clinical Biochemistry. Following receipt of his PhD in Biochemistry from the University of Connecticut Storrs, he pursued post-doctoral studies at the University of Connecticut School of Medicine in Farmington that culminated in his joint appointments in the School of Medicine and the Department of Laboratory Medicine at John Dempsey Hospital. He has numerous clinical and basic science publications and serves on various scientific and editorial boards. He is actively engaged in the training of Pathology residents and fellows in the Department of Pathology and Laboratory Medicine at Hartford Hospital. He currently serves as Vice President and Chief Scientific Officer for Clinical Laboratory Partners in Newington CT, USA.
Affiliations and expertise
Vice President and Chief Scientific Officer, Clinical Laboratory Partners, Newington, CT, USA
Read Advances in Clinical Chemistry on ScienceDirect